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Materials and methods 
 
CRISPR/Cas9-mediated down-regulation of BIF-1 and ATG7 
A375 and SK-MEL-5 melanoma cells were rendered knockout for BIF-1 (Gene ID: 51100) 
and A375 cells were additionally genome edited for loss of ATG7 (Gene ID: 10533) using a 
doxycycline-inducible bi-partite CRISPR/Cas9 system as previously described [1]. Briefly, 
specific guide RNAs (gRNA) were designed using a publicly available tool at 
http://crispor.tefor.net/ [2]. The BIF-1 knockout was conditionally prepared using the 
doxycycline-inducible vector FgH1tUTG and FUCas9Cherry plasmids (gifts from Marco 
Herold, Melbourne, Australia, and Addgene plasmids # 70183 and #70182, respectively [1]). 
The gRNA sequences were as follows: BIF-1 gRNA, 5’-TCC CAG TGA CCT TAA GGA 
GTG TAG-3’ (forward) and 5’-AAA CCT ACA CTC CTT AAG GTC ACT-3’ (reverse); 
ATG7 gRNA, 5’-TCC CGA AGC TGA ACG AGT ATC GGC-3’ (forward) and 5’- AAA CGC 
CGA TAC TCG TTC AGC TTC-3’ (reverse). Primers were synthesized by Microsynth AG 
(Balgach, DE). Recombinant lentiviral constructs were produced by calcium phosphate 
transfection together with the envelope vector PMD2.G and the packaging vector psPAX2 
(provided by Dr. D. Trono, University of Geneva, Switzerland) in 293T cells [3]. Viruses were 
harvested 24 hours after transfection, filtered through a 0.22 µm membrane (Merck Millipore, 
Burlington, Massachusetts, US), and stored at −80 °C until used. A375 and SK-MEL-5 cells 
were transduced with the desired virus in the presence of 8 µg/mL polybrene. The inducible 
BIF-1 knockout (designated thereafter BIF-/-) and ATG7 knockout cells were sorted (using 
fluorescence-activated cell sorting (FACS)) according to their GFP (FgH1UTG) and mCherry 
(FUCas9Cherry) expression to produce a population of positive cells for both markers. Control 
A375 and SK-MEL-5 lines were prepared in parallel by infecting them with a non-gRNA 
sequence containing lentiviruses. Before each experiment, cells were treated with 2.5 µg/mL 




After cell pellets were collected, cells were lysed with the appropriate amount of lysis buffer 
(50 mM Tris [pH 7.4], 150 mM NaCl, 10% Glycerol, 1% Triton X-100, 2 mM EDTA, 10 mM 
NaPyrophosphate, 50 mM NaF, 200 μM Na3VO4 and 1x PhosSTOP phosphatase inhibitor 
cocktail (Roche, Rotkreuz, Switzerland)). Lysis buffer was prepared freshly by adding 100 µM 
phenylmethylsulfonyl and protease inhibitor cocktail (Sigma-Aldrich, P-8340). The protein 
concentration was measured with the BCA Protein Assay kit (Thermo Fisher Scientific, 
23225). 50 µg of cell lysate were separated on 12% SDS-PAGE gels and transferred to a 
polyvinylidene difluoride membrane (PVDF; Immobilon-P membrane, Merck Millipore, 
IPVH304F0). After blocking in 5% milk in TBST (0.1% Tween 20 in 0.20 M Tris, 1.50 M 
NaCl [pH=7.6]) membranes were incubated with primary antibodies over-night at 4°C. 
Primary antibodies were purchased as follows: Monoclonal anti-endophilin B1/BIF-1 antibody 
(Novus Biologicals, NBP2-24733, 1:1’000), monoclonal anti-ATG7 antibody (Cell Signaling, 
8558, 1:1’000), monoclonal anti-GAPDH antibody (EMD Millipore, AM4300, 1:5’000), 
polyclonal anti-phospho-AKT (Cell Signaling, 9271, 1:1’000), polyclonal anti-AKT (Cell 
Signaling, 9272, 1:1’000), polyclonal anti-p62 (Cell Signaling, 5114, 1:1’000), polyclonal anti-
LC3 (Novus Biologicals, NB600-1384, 1:1’000), monoclonal anti-VDAC-1 antibody (Santa 
Cruz, B-6, 1:300), monoclonal anti-OGDH antibody (Cell Signaling, E1W8H, 1:1’000)  and 
monoclonal anti-alpha-tubulin (Sigma-Aldrich, T5168, 1:5’000). The membranes were washed 
three times with TBST and incubated with horseradish peroxidase (HRP)-conjugated 
secondary antibody (GE Healthcare, NA931-1ML and NA934-1ML) in blocking buffer for 1 
h at room temperature. For the detection of HRP, chemiluminescent substrate (ECL-Plus 
Western Blotting Substrate, Thermo Fisher Scientific, 32132) was used. Immunoblot signals 




Drug treatments and UV irradiation 
For in vitro anticancer drug treatment, 2 x 104 control and BIF-1 knockout A375 cells were 
seeded in 24-well plates. Cells were treated for 24 h with 2.5, 10, and 20 µg/ml etoposide 
(EBEWE Pharma GmbH Nfg. KG, Unterach am Attersee, AT), 0.1, 0.5, and 1 µM doxorubicin 
hydrochloride (Sigma-Aldrich, D1515), 1, 5, and 10 µM staurosporine (Sigma-Aldrich, 19-
123-M). For UV irradiation experiments, 2 x 105 control and BIF-1 knockout A375 cells were 
seeded in 6-well plates. The media was removed and cells were exposed to 200 x 100 µJ/cm2 
Stratalinker UV Crosslinker (model 1800, Stratagene, La Jolla, California, US) and submitted 
for cell death analyses.  
 
Cell death analysis 
Cells were washed with Annexin V staining buffer (150 mM NaCl, 4 mM KCl, 2.5 mM CaCl2, 
1 mM MgSO4, 15 mM HEPES pH 7.2, 2% FCS and 10 mM NaN3) and incubated with 
ATTO633-conjugated Annexin V diluted in staining buffer for at least 20 min on ice in the 
dark. Cells were then washed in staining buffer and resuspended in 200 μL staining buffer 
containing propidium iodide at a final concentration of 2 μg/mL. Cells were analyzed by flow 
cytometry using a FACS Lyric (BD Biosciences, Allschwil, CH). Cells double negative for 
both ATTO633-AnnexinV/propidium iodide were considered as viable cells. 
 
Transmission electron microscopy 
Cells were fixed in 2.5% (v/v) glutaraldehyde solution buffered with 0.1 M sodium cacodylate 
(pH 7.4, 340 mOsm), postfixed in OsO4 [buffered with 0.1 M sodium cacodylate (pH 7.4, 340 
mOsm)], dehydrated in graded ethanol, and embedded in EPON (Sigma-Aldrich). Blocks were 
cut with the aid of a Diatome ([Diamond Knife], Biel, CH) diamond knife and stained using 
uranyl acetate and lead citrate. Sections were examined using a Philips (Philips, Eindhoven, 
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NL) TEM CM12 with 2’650x and 19’500x magnifications. The mitochondrial area, perimeter 
and length was analyzed using the ImageJ software. 
 
Immunofluorescence 
For the immunofluorescence staining procedure, 8 x 104 A375 cells were first seeded on 
coverslips in a 24-well plate. On the following day, cells were washed with phosphate-buffered 
saline (PBS), fixed with 4% paraformaldehyde and permeabilized with 0.05% saponin 
followed by acetone treatment at −20°C. Cells were blocked with normal goat serum, bovine 
serum albumin and PBS at room temperature for 1 h. Cells were then incubated with primary 
antibody diluted in the blocking solution at 4°C overnight. The primary antibodies were as 
follows: monoclonal anti-endophilin B1/BIF-1 (dilution 1:200, Novus Biologicals, NBP2-
24733) and monoclonal anti-TOMM20 antibody (dilution, 1:200, Novus Biologicals, NBP2-
67501). Cells were washed with PBS and incubated with secondary antibodies (goat anti-rabbit 
488, goat anti-mouse 555 and goat anti-rabbit 633, Molecular Probes, Invitrogen, A21425, 
A11070 and A21071) at room temperature for 1 h. Nuclei were stained with Hoechst 
(Molecular Probes, H3570) and slides were mounted with ProLong™ Gold Antifade Mountant 
(Invitrogen, P36930). Slides were subsequently analyzed by confocal laser scanning 
microscopy (LSM 700, Carl Zeiss). The co-localisation analysis was carried out using the 
Imaris software (Bitplane AG, Zurich, Switzerland) with the Imaris Coloc tool. The % of 
occupancy of the red channel over the green channel was calculated from three independent 
experiments. The mitochondrial morphology analysis was carried out using the Imaris software 
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Supplementary Figure 1 BIF-1 mRNA expression in several cancer types. A Immunohistochemistry.
The specificity of the antibody was confirmed by immunohistochemistry using the anti-BIF-1 antibody
in control and BIF-1 knockout A375 melanoma cells. B The mRNA expression of BIF-1 in the breast
invasive carcinoma and liver hepatocellular carcinoma was obtained from the TCGA data base and
divided into two groups (“high” and “low”) based on the mean BIF-1 mRNA expression in their tumors.
Kaplan-Meier curves for overall survival are shown. The hazard ratio for OS in breast invasive
carcinoma and liver hepatocellular carcinoma of the group with “high BIF-1” expression was 0.7043; the








































































































































































Supplementary Figure 2 BIF-1 knockout has no effect on A375 melanoma cells apoptosis. A
Viability assay. Viability of control and BIF-1 knockout A375 and SK-MEL-5 melanoma cells was
assessed with ATTO633-conjugated Annexin V and PI staining. The Annexin V/PI double negative cells
were considered as viable cells. Statistical differences were analyzed by multiple t-test using the Holm-
Sidak correction method (n=3). B Viability assay. Cells were treated with etoposide (2.5 µg/ml, 10 µg/ml
or 20 µg/ml), doxorubicin (0.1 µM, 0.5 µM or 1 µM), or staurosporine (1 µM, 5 µM or 10 µM) for 24 h.
Viability was assessed with ATTO633-conjugated Annexin V and PI staining. The Annexin V/PI double
negative cells were considered as viable cells. Statistical differences were analyzed by multiple t-test
using the Holm-Sidak correction method (n=3). C Viability assay. Cells were exposed to 200 x 100
µJ/cm2 and analyzed after 12, 24 and 48 h. The Annexin V/PI double negative cells were considered as
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Supplementary Figure 3 BIF-1 localizes on mitochondria. Confocal microscopy. Co-localization of
BIF-1 and the mitochondrial marker TOMM20 was determined in A375 control cells using the Imaris
software. BIF-1 was stained with anti-BIF-1 antibody (red), mitochondria were stained with anti-
TOMM20 antibody (green) and the nuclei with Hoechst (blue). At least 20 cells from each independent
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Supplementary Figure 4 BIF-1 has an impact on mitochondrial metabolism. A and B OCR and
ECAR measurements. During extracellular flux analysis, control and BIF-1 knockout SK-MEL-5
melanoma cells were sequentially treated with oligomycin = Oligo, FCCP, rotenone/antimycin=RAA and
2-deoxy-glucose=2DG to assess the different OXPHOS (A) and glycolytic parameters (B). The
means ± SD of the mitochondrial stress test on OCR and ECAR are depicted over time. A quantitative
analysis of the data is presented on the right. Statistical differences were analyzed by multiple t-test
using the Holm-Sidak correction method (n=3). C Total intracellular ATP production in control and BIF-
1 knockout SK-MEL-5 melanoma cells was measured by ATP-dependent luciferase activity. Data are
presented as the relative luciferase units (RLU) normalized to control SK-MEL-5 melanoma cells.
Statistical differences were analyzed by the unpaired t-test (n=3). D Glucose-uptake levels in control and
BIF-1 knockout SK-MEL-5 melanoma cells. Cells were incubated in low glucose (2.5 mM) media for 8
h before analyses. Data are presented as the RLU normalized to control SK-MEL-5 melanoma cells.
Statistical differences were analyzed by the unpaired t-test (n=3). E Lactate levels in control and BIF-1
knockout SK-MEL-5 melanoma cells. Data are presented as the RLU normalized to control SK-MEL-5
melanoma cells. Statistical differences were analyzed by the unpaired t-test (n=3). *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001. (Related to Figure 3)
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Supplementary Figure 5 Autophagy does not influence glycolysis or oxidative phosphorylation in
melanoma cells. During extracellular flux analysis, ATG7 knockout A375 melanoma cells (A and B)
and A375 melanoma cells pretreated with chloroquine (10 µM for 2 h) (C and D) were sequentially
treated with oligomycin = Oligo, FCCP, rotenone/antimycin=RAA and 2-deoxy-glucose=2DG to assess




















































































































Supplementary Figure 6 BIF-1 expression impacts on the mitochondrial potential and total
mitochondrial length. A Flow cytometry. The mitochondrial potential of control and BIF-1 knockout
SK-MEL-5 melanoma cells was assessed by TMRE (100 nM) fluorescence in the presence and absence
of FCCP. Data are presented as relative geometric mean fluorescent intensities normalized to control SK-
MEL-5 melanoma cells. Statistical differences were analyzed by the unpaired t-test (n=3). B
Immunoblot. Expression of mitochondrial proteins OGDH and VDAC-1 in control and BIF-1 knockout
A375 and SK-MEL-5 melanoma cells confirms a similar mitochondrial content between BIF-1 knockout
and control melanoma cells. C-D Confocal microscopy. Mitochondria were stained with anti-TOMM20
antibody (white) and the nuclei with Hoechst (blue) in control and BIF-1 knockout A375 melanoma
cells. Representative images are shown (panel C). Mitochondria were analyzed using the Imaris software
and statistical analyses are provided for the major axis length (panel D). Approximately 80 cells per
genotype were quantified. Statistical differences were analyzed by the Mann-Whitney test. **p ≤ 0.01.
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Tables 
Supplementary Table 1. The impact of BIF-1 expression on patients’ outcome in melanoma, 
breast invasive carcinoma and liver hepatocellular carcinoma.  
 
 
Cancer type HR (95% CI)1 P-value Mean BIF-1 levels 
SKCM (N=480) 








1.503 (1.055 to 
2.110) 
0.0239 10.45 
N, Number of patients. 1The 95% confidence intervals (CI) of the hazard ratio (HR) function of the 
group with “high BIF-1” expression by log-rank test are tabulated. 
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